Citigroup’s Regulus Therapeutics RGLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-44,135
| Closed | -$77.2K | – | 5864 |
|
|
2025
Q1 | $77.2K | Sell |
44,135
-6,003
| -12% | -$7.92K | ﹤0.01% | 4731 |
|
|
2024
Q4 | $79.2K | Sell |
50,138
-3,592
| -7% | -$5.52K | ﹤0.01% | 4936 |
|
|
2024
Q3 | $84.4K | Buy |
53,730
+39,565
| +279% | +$65.5K | ﹤0.01% | 4844 |
|
|
2024
Q2 | $25.3K | Sell |
14,165
-2
| -0% | -$5 | ﹤0.01% | 4932 |
|
|
2024
Q1 | $40.8K | Buy |
14,167
+12,044
| +567% | +$19.6K | ﹤0.01% | 4721 |
|
|
2023
Q4 | $2.72K | Buy |
+2,123
| New | +$2.83K | ﹤0.01% | 5396 |
|
|
2022
Q3 | – | Sell |
-8
| Closed | – | – | 6242 |
|
|
2022
Q2 | $0 | Buy |
+8
| New | +$19 | ﹤0.01% | 6584 |
|
|
2017
Q2 | – | Sell |
-5
| Closed | -$1K | – | 7450 |
|
|
2017
Q1 | $1K | Sell |
5
-320
| -98% | -$60.9K | ﹤0.01% | 7099 |
|
|
2016
Q4 | $88K | Buy |
325
+132
| +68% | +$42.9K | ﹤0.01% | 5849 |
|
|
2016
Q3 | $77K | Buy |
193
+74
| +62% | +$30.4K | ﹤0.01% | 5386 |
|
|
2016
Q2 | $41K | Sell |
119
-156
| -57% | -$112K | ﹤0.01% | 5689 |
|
|
2016
Q1 | $229K | Buy |
275
+173
| +170% | +$138K | ﹤0.01% | 4958 |
|
|
2015
Q4 | $106K | Sell |
102
-17
| -14% | -$17K | ﹤0.01% | 5330 |
|
|
2015
Q3 | $94K | Sell |
119
-57
| -32% | -$58.5K | ﹤0.01% | 5023 |
|
|
2015
Q2 | $233K | Hold |
176
| – | – | ﹤0.01% | 4318 |
|
|
2015
Q1 | $357K | Sell |
176
-10
| -5% | -$21.7K | ﹤0.01% | 4044 |
|
|
2014
Q4 | $358K | Buy |
186
+180
| +3,000% | +$320K | ﹤0.01% | 4198 |
|
|
2014
Q3 | $4K | Buy |
6
+5
| +500% | +$4.23K | ﹤0.01% | 6657 |
|
|
2014
Q2 | $1K | Sell |
1
-42
| -98% | -$36K | ﹤0.01% | 6943 |
|
|
2014
Q1 | $46K | Sell |
43
-9
| -17% | -$9.98K | ﹤0.01% | 5537 |
|
|
2013
Q4 | $46K | Buy |
+52
| New | +$44.8K | ﹤0.01% | 5763 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 6946 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 6785 |
|
Other funds holding RGLS
Citigroup's RGLS Position: Q2 2025 in Review
Citigroup sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 44,135 shares — an estimated $77.2K sold.
Citigroup first reported a position in RGLS in Q4 2013 and held it in 21 quarters. The position peaked at $358K in Q4 2014. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.
- Citigroup reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
- Citigroup sold 44,135 Regulus Therapeutics shares in Q2 2025, an estimated $77.2K.
- Citigroup first reported a position in Regulus Therapeutics in Q4 2013 and held it in 21 quarters.
- Citigroup's Regulus Therapeutics position peaked at $358K in Q4 2014.
- 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.
Based on Citigroup's 13F filing for Q2 2025, filed 11 Aug 2025.